文献速递血栓与止血

低剂量地西他滨调节ITP患者T细胞稳态并恢复免疫耐受

Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia.
PubMed 文献 · Blood · 2021-01-01

本研究探讨低剂量地西他滨对免疫性血小板减少症(ITP)T细胞亚群的影响。体外及动物实验显示该药促进调节性T细胞(Treg)生成并增强其抑制功能,缓解小鼠血小板减少;患者用药后Treg数量与功能改善,Th1和Th17受抑,炎性因子下降,磷酸化STAT3下调。

要点

  • 低剂量地西他滨促进Treg生成、分化并增强其免疫抑制功能。
  • 在ITP小鼠中减轻血小板减少,恢复Treg与辅助性T细胞平衡。
  • 患者用药后Treg数量功能改善、Th1/Th17受抑,可能与抑制STAT3激活有关。

核心结论

  • 低剂量地西他滨的免疫调节作用为ITP持续缓解提供了可能的机制解释。

研究设计与样本

  • 研究分析地西他滨在体外和体内对ITP T细胞亚群的影响。
  • 采用CD61敲除小鼠经CD61+血小板免疫后脾细胞过继转移至重度联合免疫缺陷小鼠诱导ITP模型。

主要发现

  • 低剂量地西他滨促进Treg细胞生成与分化并增强其免疫抑制功能。
  • 低剂量地西他滨减轻活动性ITP小鼠血小板减少并恢复Treg与辅助性T细胞平衡。
  • Treg删除和耗竭抵消地西他滨恢复ITP小鼠CD4+ T细胞亚群的效果。
  • 患者接受低剂量地西他滨后Treg数量与功能显著改善,Th1和Th17较治疗前受抑。
  • RNA测序和细胞因子分析显示地西他滨重新平衡T细胞稳态、降低促炎细胞因子并下调磷酸化STAT3。

临床怎么用

  • 低剂量地西他滨可能通过调节T细胞免疫耐受为难治性ITP提供治疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our previous clinical study showed that low-dose decitabine exhibited sustained responses in nearly half of patients with refractory immune thrombocytopenia (ITP). The long-term efficacy of decitabine in ITP is not likely due to its simple role in increasing platelet production. Whether decitabine has the potential to restore immune tolerance in ITP is unknown. In this study, we analyzed the effect of decitabine on T-cell subpopulations in ITP in vitro and in vivo. We found that low-dose decitabine promoted the generation and differentiation of regulatory T (Treg) cells and augmented their immunosuppressive function. Splenocytes from CD61 knockout mice immunized with CD61+ platelets were transferred into severe combined immunodeficient mouse recipients to induce a murine model of ITP. Low-dose decitabine alleviated thrombocytopenia and restored the balance between Treg and helper T (Th) cells in active ITP mice. Treg deletion and depletion offset the effect of decitabine in restoring CD4+ T-cell subpopulations in ITP mice. For patients who received low-dose decitabine, the quantity and function of Treg cells were substantially improved, whereas Th1 and Th17 cells were suppressed compared with the pretreatment levels. Next-generation RNA-sequencing and cytokine analysis showed that low-dose decitabine rebalanced T-cell homeostasis, decreased proinflammatory cytokines, and downregulated phosphorylated STAT3 in patients with ITP. STAT3 inhibition analysis suggested that low-dose decitabine might restore Treg cells by inhibiting STAT3 activation. In conclusion, our data indicate that the immunomodulatory effect of decitabine provides one possible mechanistic explanation for the sustained response achieved by low-dose decitabine in ITP.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Han P, Hou Y, Zhao Y, et al. Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood. 2021. PMID: 33876188. doi:10.1182/blood.2020008477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。